Effect of COVID-19 and HBV Coinfection on Risk of Death from COVID-19: A Meta-analysis
Abstract – COVID-19 is a novel coronavirus that was first seen in Wuhan, China, in late 2019. Since then, it has caused a global pandemic, and many new strains of COVID-19 arose. Because of how transmissible COVID-19 is, it has infected patients with other comorbidities, such as HIV, diabetes, and liver cirrhosis. Other studies have investigated how those diseases have impacted mortality in COVID-19 patients. This study aims to investigate how hepatitis B virus (HBV) impacts risk of mortality in COVID-19 patients. Data for this meta-analysis was found through searching PubMed, Cochrane Library, and EMBASE on June 20th, 2022. Both retrospective and prospective studies were included in this meta-analysis, and inclusion criteria mainly required available data and no population restrictions. Some studies were excluded due to lack of events and data. Mortality was the primary outcome of this study. 12 studies with a total of 298404 patients were included within this meta-analysis, and the impact of all-cause mortality while infected with COVID-19 was not impacted by HBV by a statistically significant amount (OR = 1.54, 95% CI: 0.93 to 2.56, p value = 0.10). Significant heterogeneity was found in this study (I2 = 87%). From the results, it does not seem patients with both HBV and COVID-19 have a much higher risk of mortality compared other COVID-19 patients. Further studies could be done on HBV and COVID-19 co-infections, HBV and vaccine interactions, and HBV and COVID-19 co-infections with new strains of COVID-19.